Third Harmonic Bio Inc is a clinical-stage company developing a novel oral approach to the treatment of severe allergy and inflammation. Third Harmonic Bio Inc is a clinical-stage company developing a novel oral approach to the treatment of severe allergy and inflammation.
SAN FRANCISCO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal...
SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal...
THB335 Phase 1 SAD/MAD clinical trial progressing; study now on track to report clinical results in 1Q’25 Strong financial position with cash and cash equivalents totaling $255.3 million as of...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.43 | 3.43176376696 | 12.53 | 13.18 | 11.99 | 93074 | 12.29293634 | CS |
4 | -0.54 | -4 | 13.5 | 16.02 | 11.65 | 356854 | 13.46411313 | CS |
12 | 1.03 | 8.63369656329 | 11.93 | 16.02 | 10.225 | 164927 | 13.09198585 | CS |
26 | 1.56 | 13.6842105263 | 11.4 | 16.94 | 10.135 | 138512 | 12.83303765 | CS |
52 | 6.32 | 95.1807228916 | 6.64 | 16.94 | 5.765 | 140763 | 11.05417005 | CS |
156 | -27.91 | -68.2896990458 | 40.87 | 40.87 | 3.75 | 108306 | 9.10603821 | CS |
260 | -27.91 | -68.2896990458 | 40.87 | 40.87 | 3.75 | 80508 | 9.10603821 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.